Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

64.46
Delayed Data
As of Jul 30
 -0.43 / -0.66%
Today’s Change
47.55
Today|||52-Week Range
70.54
+9.20%
Year-to-Date
3 Stocks Pushing The Drugs Industry Downward
Jul 30 / TheStreet.com
Bristol-Myers (BMY) Beats on Q2 Earnings, Updates View - Tale of the Tape
Jul 23 / Zacks.com
Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog
Jul 29 / Zacks.com
Investors join push for more transparency on drug trials
Jul 22 / FT.com
Procter & Gamble Reports Plunging Sales, and Incoming CEO Should Be Worried
Jul 28 / TheStreet.com
Bristol-Myers' HIV-1 Inhibitor Gets Breakthrough Designation - Analyst Blog
Jul 22 / Zacks.com
Are These 2 Big Pharmas Really Buyout Candidates?
Jul 28 / MotleyFool.com
2015bs Top 6 Big Pharma Headlines Thus Far
Jul 22 / MotleyFool.com
Is the U.S. Bull Market Starting to Lose Its Luster?
Jul 27 / TheStreet.com
Bristol-Myers' Opdivo Study Stopped Early, Meets Endpoint - Analyst Blog
Jul 21 / Zacks.com
4 Stocks to Fight the Virus on World Hepatitis Day - Analyst Blog
Jul 27 / Zacks.com
Can Bristol-Myers (BMY) Keep its Earnings Streak Alive? - Analyst Blog
Jul 21 / Zacks.com
Is Bristol-Myers Squibb Outpacing Johnson & Johnson?
Jul 25 / MotleyFool.com
Potential Kidney Cancer Drugs Could Revolutionize Treatment
Jul 21 / MotleyFool.com
Bristol-Myers Squibb (BMY) Earnings Report: Q2 2015 Conference Call Transcript
Jul 24 / TheStreet.com
Bristol-Myers' HIV-1 Drug Evotaz Gets European Approval - Analyst Blog
Jul 17 / Zacks.com
Bristol-Myers Squibb Gets a Mixed Message From Investors
Jul 23 / MotleyFool.com
Drugmakers premiere summer blockbusters
Jul 12 / FT.com
Merck's Anti-PD-1 Therapy Melanoma Drug Gets EU Nod - Analyst Blog
Jul 23 / Zacks.com
AstraZeneca rises on drug pipeline hopes
Jul 02 / FT.com
Bristol-Myers Beats on Q2 Earnings, Raises 2015 Guidance - Analyst Blog
Jul 23 / Zacks.com